[1] Vini L and Harmer C (2000) Radioiodine treatment for differentiated thyroid cancer.
[2] Matheoud R, Canzi C, Reschini E, Zito F, Voitini F,Gerundini P (2003) Tissue-specific dosimetry for radioiodine therapy of the autonomous thyroid nodule.
[3] Kim WG, Ryu JS, Kim EY, Lee JH, Baek JH, Yoon JH, Hong SH, Kim ES, Kim TY, Kim WB, Shong YK(2010) Empiric high-dose Iodine-131 therapy lacks efficacy for treated papillary thyroid cancer patients with detectable serum thyroglobulin, but negative cervical sonograph and 18F-fluorodeoxyglucose positron emission tomography scan.
[4] Sgouros G, Hobbs RF, Atkins FB, Nostrand DV,Ladenson PW, Wahl RL(2011) Three-dimensional radiobiological dosimetry (3D-RD) with 124I PET for 131I therapy of thyroid cancer.
[5] Cooper DS, Doherty GM,Haugen BR, Kloos RT,et all.(2006) Management guidelines for patients with thyroid nodules and differentiated thyroid cancer.
[6] Krstic, Dragana, et all.(2014) MCNP Simulation of the dose distribution in Liver cancer treatment for BNC therapy.
[7] Agita A(2011) Simulation Penentuan Dosis Serapan Pada Brachytherapy Prostat Menggunakan Software MCNP5.
[8] Cristy M(1980) Mathematical Phantom Representing Children of Various Ages for Use in Estimates of Internal dose.Oak Ridge National Laboratory.